EMA Sets Deadline for Women's Health Regulatory Roadmap After Amsterdam Workshop

A Q4 2026 publication deadline for EMA's women's health regulatory roadmap means regulatory affairs and QA teams have a narrow window to conduct gap assessments before new expectations around clinical trial design, sex-disaggregated data reporting, and lifecycle evidence generation take shape. The roadmap follows a multistakeholder workshop held on 28–29 September in Amsterdam, where more than 100 participants, spanning regulators, patients, healthcare professionals, NGOs, industry, and academia, converged on 10 priority actions.

The core finding driving the initiative is structural: persistent gaps in research and evidence generation leave women's specific health needs insufficiently characterised across the medicines lifecycle. For regulatory affairs leads, the implications reach into ICH E5 territory and beyond, the priority actions explicitly call for improved enrolment of women in clinical trials, inclusion of pregnant and breastfeeding individuals, and mandatory reporting of high-quality sex-disaggregated data.

The 10 agreed actions span short-, medium-, and long-term deliverables. Operationally relevant items include early and lifecycle-wide evidence generation with women of all ages in scope, a sustainable real-world data infrastructure, and a framework of measurable KPIs with regular progress reporting. EMA also committed to training the European medicines regulatory network on sex- and gender-sensitive assessment, a signal that assessor expectations during submissions and variations may shift once the roadmap is formalised.

For plant heads and QA directors, the real-world data and lifecycle evidence requirements are the most immediate planning consideration. Sponsors running ongoing programmes should review whether current post-authorisation safety study designs and pharmacovigilance plans adequately stratify by sex and life stage. Gaps identified now are considerably cheaper to address than protocol amendments filed after the roadmap establishes binding or guideline-level expectations.

The workshop report and roadmap are both scheduled for release by end of 2026, giving industry a defined horizon against which to benchmark internal readiness assessments.

Source: European Medicines Agency (EMA) via ema.europa.eu, 30 September 2026.